Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DYAI

Dyadic International Inc., DE

Apr 01 • 04:00PM ET

1.38

Dollar change +0.03
Percentage change 2.22	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX REGN ILMN INCY NBIX NKTR EXEL

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.20	Insider Own	30.74%	Shs Outstand	29.84M	Perf Week	0.00%
Market Cap	41.52M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.00%	Shs Float	20.84M	Perf Month	-1.43%
Income	-5.81M	PEG	-	EPS next Q	-	Inst Own	17.01%	Short Float	0.46%	Perf Quarter	-29.59%
Sales	3.50M	P/S	11.86	EPS this Y	-15.00%	Inst Trans	10.34%	Short Ratio	1.48	Perf Half Y	25.45%
Book/sh	0.08	P/B	16.67	EPS next Y	0.00%	ROA	-64.01%	Short Interest	0.10M	Perf Year	-17.37%
Cash/sh	0.31	P/C	4.48	EPS next 5Y	-	ROE	-139.16%	52W Range	0.93 - 2.67	Perf YTD	-21.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.43%	ROI	-77.64%	52W High	-48.31%	Beta	0.98
Dividend TTM	-	Quick Ratio	4.01	Sales past 5Y	17.35%	Gross Margin	65.82%	52W Low	49.08%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.01	EPS Y/Y TTM	15.90%	Oper. Margin	-168.17%	RSI (14)	46.45	Volatility	6.07% 7.77%
Employees	6	Debt/Eq	2.05	Sales Y/Y TTM	20.58%	Profit Margin	-166.19%	Recom	1.00	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	2.03	EPS Q/Q	27.68%	Payout	-	Rel Volume	0.38	Prev Close	1.35
Sales Surprise	-49.04%	EPS Surprise	-25.00%	Sales Q/Q	19.06%	Earnings	Mar 26 AMC	Avg Volume	64.81K	Price	1.38
SMA20	-1.24%	SMA50	-5.64%	SMA200	-2.83%	Trades		Volume	24,773	Change	2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Downgrade	Dawson James	Buy → Neutral
Dec-17-21	Initiated	H.C. Wainwright	Buy	$7

Mar-27-25 08:00AM	Q4 2024 Dyadic International Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Dyadic International Inc (DYAI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Mar-26-25 10:58PM	Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	Dyadic Reports 2024 Year-End Financial Results and Business Updates (GlobeNewswire)
Mar-25-25 09:04AM	What To Expect From Dyadic International Inc (DYAI) Q4 2024 Earnings (GuruFocus.com)
08:30AM	Loading…
Mar-20-25 08:30AM	Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines (GlobeNewswire)
Mar-12-25 04:00PM	Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025 (GlobeNewswire)
Mar-06-25 08:30AM	Dyadic to Attend Multiple Industry Events in March (GlobeNewswire)
Jan-06-25 08:30AM	Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Nov-21-24 08:30AM	Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology (GlobeNewswire) +12.08%
Nov-13-24 02:21AM	Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Nov-12-24 04:05PM	Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets (GlobeNewswire) +8.57%
Nov-11-24 07:27AM	Earnings To Watch: Dyadic International Inc (DYAI) Reports Q3 2024 Result (GuruFocus.com) -7.89%
Nov-04-24 04:30PM	Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-09-24 06:19PM	Dyadic International Inc (DYAI) Q2 2024 Earnings Call Highlights: Strategic Positioning Amid ... (GuruFocus.com)
08:00AM	Loading…
08:00AM	Dyadic Expands Global Presence with Participation in Key Industry Events (GlobeNewswire)
Sep-23-24 09:50AM	Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference (GlobeNewswire)
Aug-13-24 04:05PM	Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jul-30-24 04:00PM	Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 (GlobeNewswire)
Jun-28-24 08:30AM	Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership (GlobeNewswire) -6.33%
May-30-24 04:30PM	Dyadic to Attend Industry Events in June (GlobeNewswire) +5.58%
May-15-24 05:01PM	Dyadic International Inc (DYAI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review ... (GuruFocus.com) +5.37% +5.73%
May-14-24 08:57PM	DYAI Stock Earnings: Dyadic International Reported Results for Q1 2024 (InvestorPlace)
04:00PM	Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-08-24 08:30AM	Dyadic to Attend Industry and Investor Events in May (GlobeNewswire)
Apr-30-24 04:30PM	Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 (GlobeNewswire)
Apr-01-24 12:24PM	Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 07:18AM	Q4 2023 Dyadic International Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 08:53PM	DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	Dyadic Reports 2023 Full Year Results and Recent Company Progress (GlobeNewswire)
08:30AM	Loading…
08:30AM	Dyadic Announces Change in Board and Management Leadership Roles (GlobeNewswire)
Mar-27-24 08:30AM	Dyadic to Attend Industry Events in April (GlobeNewswire)
Mar-26-24 08:30AM	Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications (GlobeNewswire)
Mar-21-24 08:30AM	Dyadic to Attend Future Food Tech Event March 21 22, 2024 in San Francisco, California (GlobeNewswire)
Mar-14-24 04:30PM	Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 (GlobeNewswire) -5.00%
Mar-11-24 09:57AM	CORRECTION Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization (GlobeNewswire) +5.80%
08:30AM	Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization (GlobeNewswire)
Mar-01-24 08:30AM	Dyadic to Attend Industry Events in March (GlobeNewswire)
Feb-28-24 08:30AM	Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform (GlobeNewswire)
Feb-23-24 02:00AM	Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions (GlobeNewswire)
Feb-21-24 08:30AM	Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions (GlobeNewswire) +11.85%
Feb-13-24 08:30AM	Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing (GlobeNewswire)
Feb-06-24 08:30AM	Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company (GlobeNewswire)
Feb-01-24 08:30AM	Dyadic to Attend BIO CEO & Investor Conference and European Industry Events (GlobeNewswire) +6.15%
Jan-22-24 08:00AM	Dyadic International, Inc Invites You to Join Us at The Microcap Conference (Newsfile)
Jan-02-24 08:30AM	Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference (GlobeNewswire)
Nov-30-23 08:30AM	Dyadic Attends Investor Events in December (GlobeNewswire)
Nov-29-23 08:30AM	Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate (GlobeNewswire)
Nov-20-23 08:30AM	Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa (GlobeNewswire) +5.85%
Nov-09-23 03:54PM	Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:15PM	Dyadic International Inc (DYAI) Reports Decrease in Q3 Revenue and Net Loss Improvement ... (GuruFocus.com)
04:00PM	Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-30-23 08:30AM	Dyadic to Present at Industry Events in November (GlobeNewswire) +5.23%
Oct-25-23 04:30PM	Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 (GlobeNewswire)
Oct-17-23 07:28AM	DYAI: Fall Update (Zacks)
Oct-09-23 08:30AM	Dyadic Appoints Doug Pace to Its Executive Leadership Team (GlobeNewswire)
Oct-05-23 08:30AM	Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ( VIC ) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases (GlobeNewswire)
Sep-29-23 08:30AM	Dyadic to Present at Industry and Investor Events in October (GlobeNewswire)
Sep-26-23 08:30AM	Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells (GlobeNewswire) -8.65%
Sep-19-23 08:00AM	Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus (GlobeNewswire)
Sep-12-23 04:30PM	Dyadic to Present at BioProcess International (GlobeNewswire)
Aug-11-23 09:14AM	DYAI: MoUs Highlight C1 Vaccine Potential (Zacks)
Aug-09-23 04:00PM	Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +10.00%
Aug-07-23 08:30AM	Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin (GlobeNewswire)
Jul-26-23 04:30PM	Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 (GlobeNewswire)
Jul-24-23 08:30AM	Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate (GlobeNewswire)
Jun-21-23 08:33AM	Dyadic Announced an MoU with Bangladeshs State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity (GlobeNewswire)
Jun-01-23 08:30AM	Dyadic to Participate at Upcoming Events in June (GlobeNewswire)
May-12-23 06:32AM	Dyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three years (Simply Wall St.)
May-11-23 11:18AM	DYAI: Abundant Opportunities in Products and Animal & Human Health (Zacks Small Cap Research) +10.47%
May-10-23 04:00PM	Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
08:30AM	Dyadic to Participate at Two Industry Events in May (GlobeNewswire)
May-08-23 08:30AM	Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus (GlobeNewswire) +5.93%
Apr-26-23 04:30PM	Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (GlobeNewswire) +16.02%
Apr-18-23 08:30AM	Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform (GlobeNewswire) -9.92%
Apr-12-23 08:00AM	Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent (GlobeNewswire)
Apr-01-23 12:47PM	Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript (Insider Monkey)
09:09AM	Dyadic International Full Year 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Mar-30-23 10:29AM	DYAI: 2022 Results (Zacks Small Cap Research) +19.80%
08:30AM	Dyadic to Present at World Vaccine Congress Washington 2023 (GlobeNewswire)
Mar-29-23 04:00PM	Dyadic Reports 2022 Year End Results and Recent Company Progress (GlobeNewswire)
Mar-15-23 08:30AM	Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023 (GlobeNewswire)
Mar-12-23 10:08AM	Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation (Simply Wall St.)
Mar-07-23 08:30AM	Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate (GlobeNewswire) +19.86%
Mar-01-23 08:30AM	Dyadic to Present at Roth Investor Conference and Upcoming Industry Events (GlobeNewswire) +9.49%
Feb-02-23 08:30AM	Dyadic to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-31-23 05:56AM	DYAI: First Patient Administered C1 Derived Vaccine (Zacks Small Cap Research)
Jan-24-23 08:30AM	Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate (GlobeNewswire)
Jan-19-23 08:30AM	Dyadic Announces Sale of Equity Interest in Alphazyme (GlobeNewswire)
Jan-04-23 08:30AM	Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference (GlobeNewswire)
Dec-14-22 08:30AM	Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal (GlobeNewswire)
Nov-11-22 07:10AM	DYAI: DYAI-100 Phase I in the Spotlight (Zacks Small Cap Research) -8.70%
Nov-10-22 04:00PM	Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments (GlobeNewswire)
Nov-07-22 08:30AM	Dyadic to Present at Upcoming Industry and Investor Events in November (GlobeNewswire)
Nov-04-22 10:33AM	Those who invested in Dyadic International (NASDAQ:DYAI) five years ago are up 63% (Simply Wall St.) -6.03%
Oct-27-22 04:30PM	Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (GlobeNewswire)
09:04AM	Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate (GlobeNewswire)
Oct-04-22 08:45AM	Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential (GlobeNewswire) -7.81%
Sep-13-22 08:00AM	Dyadic Updates Market on Recent Scientific Achievements (GlobeNewswire) -5.75%
Sep-11-22 08:15AM	We're Keeping An Eye On Dyadic International's (NASDAQ:DYAI) Cash Burn Rate (Simply Wall St.)

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Francisco Trust under agreemen	Greater than 10% holder	Mar 31 '25	Proposed Sale	1.41	215,793	304,269		Mar 31 04:00 PM
Kaye Jack	Director	Mar 05 '25	Option Exercise	1.33	30,000	39,900	87,166	Mar 07 04:07 PM
HERBST SETH	Director	Jan 06 '25	Option Exercise	0.97	25,000	24,250	180,759	Jan 08 05:19 PM
Francisco Trust under agreemen	Greater than 10% holder	Dec 20 '24	Proposed Sale	1.91	295,893	563,676		Dec 20 03:56 PM
Tarnok Michael P.	Director	Nov 22 '24	Option Exercise	0.97	25,000	24,250	246,672	Nov 25 11:59 AM
Buckland Barry	Director	Jun 11 '24	Option Exercise	1.59	11,793	18,751	38,967	Jun 13 09:26 PM
Tarnok Michael P.	Director	May 21 '24	Option Exercise	1.36	30,000	40,800	246,103	May 23 03:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DYAI

Dyadic International Inc., DE

Upgrade your FINVIZ experience